Morocco is making significant progress in improving access to essential medications for attention deficit hyperactivity disorder (ADHD) by advancing the pricing process for the ADHD medication Concerta, also known as methylphenidate. The Moroccan Agency for Medicines and Health Products has officially granted marketing authorizations for Concerta in three different strengths: 18 mg, 36 mg, and 54 mg. This development marks a critical step towards making Concerta more accessible to patients who require this medication for effective management of ADHD symptoms.
Currently, the agency has completed the public pricing process for the 36 mg and 54 mg formulations and is now awaiting the publication of pricing decisions in the Official Gazette, which is a necessary prerequisite before these strengths can be marketed to the public. Meanwhile, the 18 mg strength is still undergoing a price review, indicating that the process is thorough and aims to ensure fair pricing for consumers. This initiative reflects Morocco's commitment to enhancing healthcare access and ensuring that individuals with ADHD can obtain the necessary treatments without undue financial burden.
As reported by navlindaily.com.
